1. Scrip
  2. >>Business
  3. >>Earnings

Bayer Talks Up Pharma Prospects Post-Xarelto

 
• By Kevin Grogan

The pharmaceutical division is expected to be the three-pillared German group's primary growth driver for the foreseeable future and the launch of new cardiovascular and woman's health products should help manage the loss of exclusivity on Bayer's biggest earner.

Anderson
CEO Bill Anderson at Bayer's news conference in London on 5 March, flanked by chief talent officer Heike Prinz and CFO Wolfgang Nickl • Source: Bayer

Now that Bayer AG has decided not to break up the business, the company has been reflecting on what needs to improve at its pharmaceuticals division to cope with a considerable patent cliff and help with pipeline prioritization.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

More from Business